This inventor holds 1 USPTO granted patent. Top assignees: Jsr Corporation, National University Corporation Tokai National Higher Education and Research System. Active years: 2026.
Company Filing History:

Years Active: 2026
Title: Kohei Matsuoka: Innovator in Photoimmunotherapy
Introduction
Kohei Matsuoka is a notable inventor based in Nagoya, Japan. He has made significant contributions to the field of photoimmunotherapy, particularly through his innovative patent. His work focuses on the development of conjugates that enhance the effectiveness of cancer treatments.
Latest Patents
Matsuoka holds a patent for a conjugate useful in photoimmunotherapy. This conjugate includes an antibody molecule, a particle with an average diameter of 100 nm or less, and a photosensitive portion. The unique aspect of this invention is that the particle is linked to the antibody molecule, and at least one of these components is bound to the photosensitive portion. This photosensitive portion exhibits increased hydrophobicity when exposed to light beams with wavelengths ranging from 500 nm to 900 nm, or it may contain a phthalocyanine skeleton. Matsuoka's patent represents a significant advancement in targeted cancer therapies.
Career Highlights
Throughout his career, Matsuoka has worked with prominent organizations, including JSR Corporation and the National University Corporation Tokai National Higher Education and Research System. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Matsuoka has collaborated with notable colleagues such as Kazuhide Sato and Hiroshi Yukawa. These partnerships have further enriched his research and development efforts in the realm of photoimmunotherapy.
Conclusion
Kohei Matsuoka is a pioneering inventor whose work in photoimmunotherapy has the potential to transform cancer treatment. His innovative approaches and collaborations highlight the importance of research in advancing medical science.